AR092103A1 - Laquinimod en el tratamiento de los trastornos mediados por el receptor de canabinoides del tipo 1 (cb1) - Google Patents

Laquinimod en el tratamiento de los trastornos mediados por el receptor de canabinoides del tipo 1 (cb1)

Info

Publication number
AR092103A1
AR092103A1 ARP130102858A ARP130102858A AR092103A1 AR 092103 A1 AR092103 A1 AR 092103A1 AR P130102858 A ARP130102858 A AR P130102858A AR P130102858 A ARP130102858 A AR P130102858A AR 092103 A1 AR092103 A1 AR 092103A1
Authority
AR
Argentina
Prior art keywords
laquinimod
treatment
canabinoid
receiver
type
Prior art date
Application number
ARP130102858A
Other languages
English (en)
Inventor
Centonze Diego
Martino Gianvito
Original Assignee
Teva Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teva Pharma filed Critical Teva Pharma
Publication of AR092103A1 publication Critical patent/AR092103A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4704—2-Quinolinones, e.g. carbostyril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Método para tratar un sujeto humano que padece un trastorno relacionado con el receptor CB1, que comprende administrarle periódicamente al sujeto una cantidad eficaz para efectuar el tratamiento de laquinimod o de una sal farmacéuticamente aceptable de éste.
ARP130102858A 2012-08-13 2013-08-12 Laquinimod en el tratamiento de los trastornos mediados por el receptor de canabinoides del tipo 1 (cb1) AR092103A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201261682574P 2012-08-13 2012-08-13

Publications (1)

Publication Number Publication Date
AR092103A1 true AR092103A1 (es) 2015-03-25

Family

ID=50066661

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP130102858A AR092103A1 (es) 2012-08-13 2013-08-12 Laquinimod en el tratamiento de los trastornos mediados por el receptor de canabinoides del tipo 1 (cb1)

Country Status (8)

Country Link
US (2) US20140045887A1 (es)
EP (1) EP2882495A4 (es)
AR (1) AR092103A1 (es)
CA (1) CA2881974A1 (es)
IL (1) IL237043A0 (es)
MX (1) MX2015001889A (es)
TW (1) TW201410243A (es)
WO (1) WO2014028399A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013116657A1 (en) 2012-02-03 2013-08-08 Teva Pharmaceutical Industries Ltd. USE OF LAQUINIMOD FOR TREATING CROHN'S DISEASE PATIENTS WHO FAILED FIRST-LINE ANTI-TNFα THERAPY
MX2014009889A (es) 2012-02-16 2014-11-13 Teva Pharma N-etil-n-fenil-1,2-dihidro-4,5-di-hidroxi-1-metil-2-oxo-3-quinoli ncarboxamida, preparacion y usos de los mismos.
TW201400117A (zh) 2012-06-05 2014-01-01 Teva Pharma 使用拉喹莫德治療眼發炎疾病
TW201410244A (zh) 2012-08-13 2014-03-16 Teva Pharma 用於治療ｇａｂａ媒介之疾病之拉喹莫德（ｌａｑｕｉｎｉｍｏｄ）
EA201590788A1 (ru) 2012-11-07 2015-12-30 Тева Фармасьютикал Индастриз Лтд. Аминные соли лахинимода
JP2016514162A (ja) 2013-03-14 2016-05-19 テバ ファーマシューティカル インダストリーズ リミティド ラキニモドナトリウムの結晶およびその製造のための改善された方法
BR112016014507A2 (pt) * 2013-12-20 2018-05-22 Teva Pharma uso de laquinimod para retardar progressão da doença de huntington
HK1231413A1 (zh) 2014-04-29 2017-12-22 Teva Pharmaceutical Industries Ltd. 用於治疗具有高残疾状况的复发-缓解型多发性硬化症(rrms)的患者的拉喹莫德

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6077851A (en) * 1998-04-27 2000-06-20 Active Biotech Ab Quinoline derivatives
TW200522944A (en) * 2003-12-23 2005-07-16 Lilly Co Eli CB1 modulator compounds
CA2613678A1 (en) * 2005-06-02 2006-12-07 Glenmark Pharmaceuticals S.A. Novel cannabinoid receptor ligands, pharmaceutical compositions containing them, and process for their preparation
CN101466379B (zh) * 2006-06-12 2012-10-31 泰华制药工业有限公司 稳定的拉喹莫德的制剂
US8354428B2 (en) * 2008-07-01 2013-01-15 Actavis Group Ptc Ehf Solid state forms of laquinimod and its sodium salt
AU2009313927A1 (en) * 2008-11-13 2010-05-20 Astrazeneca Ab Azaquinolinone derivatives and uses thereof
WO2011019375A1 (en) * 2009-08-10 2011-02-17 Teva Pharmaceutical Industries Ltd. Treatment of bdnf-related disorders using laquinimod

Also Published As

Publication number Publication date
TW201410243A (zh) 2014-03-16
IL237043A0 (en) 2015-03-31
MX2015001889A (es) 2015-05-07
CA2881974A1 (en) 2014-02-20
WO2014028399A1 (en) 2014-02-20
EP2882495A1 (en) 2015-06-17
EP2882495A4 (en) 2016-04-06
US20160310481A1 (en) 2016-10-27
US20140045887A1 (en) 2014-02-13

Similar Documents

Publication Publication Date Title
MX2020001732A (es) Tratamiento de las afecciones del sistema nervioso central.
MX2015012867A (es) Compuestos aromaticos multisustituidos como inhibidores de serina proteasa.
EA201590655A1 (ru) Комбинация лахинимода и придопидина для лечения нейродегенеративных нарушений
MX365939B (es) Moduladores del transporte nuclear y usos de los mismos.
NZ737399A (en) Ccr2 modulators
MX2018000396A (es) Compuestos aza sustituidos como inhibidores de cinasa 4 asociada al receptor de interleucina 1 (irak-4).
SV2016005311A (es) Compuestos y composiciones como agonistas del receptor tipo toll 7
PH12016502382A1 (en) Substituted indazole compounds as irak4 inhibitors
MX2016014308A (es) Compuestos y composiciones como agonistas del receptor tipo toll 7.
MX385332B (es) Moduladores de ror-gamma.
CO6630082A2 (es) Tratamiento de lupus nefritis usando laquinimod
MX365525B (es) Compuestos que regulan la expresión de subunidades alfa de canales de sodio regulados por voltaje en enfermedades relacionadas con epilepsia mioclónica severa de la infancia.
NZ702663A (en) Nuclear transport modulators and uses thereof
MX2015016100A (es) Inhibidores de criopirina para prevenir y tratar la inflamacion.
MX2022007221A (es) Compuestos y composiciones para el tratamiento o prevencion de trastornos patologicos asociados con exceso de deposicion de fibrina y/o formacion de trombos.
MX390084B (es) Moduladores del receptor p2x3 y p2x2/3 de diaminopirimidina para usarse en el tratamiento de la tos.
AR099707A1 (es) Composiciones y métodos para tratar trastornos renales
PH12020500285B1 (en) Use of agonists of formly peptide receptor 2 for treating ocular inflammatory diseases
MX2015006720A (es) D-metadona para el tratamiento de sintomas psiquiatricos.
EA201691567A1 (ru) Способы лечения легких травм головного мозга
TN2014000046A1 (en) Substituted 3-(biphenyl-3-yl)-4-hydroxy-8-methoxy-1-azaspiro[4.5]dec-3-en-2-one
GEAP201914284A (en) Pyridazine derivatives for use in the prevention or treatment of an ataxic disorder
MX356317B (es) Tratamiento de síntomas asociados a gastroparesia femenina.
AR092104A1 (es) LAQUINIMOD EN EL TRATAMIENTO DE LOS TRASTORNOS MEDIADOS POR EL ACIDO g-AMINOBUTIRICO (GABA)
MX2016008968A (es) Compuestos organicos.

Legal Events

Date Code Title Description
FB Suspension of granting procedure